Popular
GANX · Medicine & biotech · U.S.

Gain Therapeutics

Develops a pill meant to slow Parkinson’s disease.

Company Health

Its yearly reports don’t have enough numbers to give it a score.
Its yearly figures are still below.

Who owns it

1 of 23 own it · Nobody changed their stake
bought lately
owns it
doesn’t own it
Didn’t report owning it: Whale Rock, Appaloosa, Melqart, Coatue, D1 Capital, Light Street, Lone Pine, Third Point, TCI, Pershing Square, Duquesne, Himalaya Capital, Giverny Capital, Fundsmith, Semper Augustus, Akre
Their letters don’t mention it: Arquitos, Laughing Water, Alluvial, Bireme, Kingdom Capital, Saga Partners
From each fund’s latest 13F report (Jun 30, 2026). Funds that don’t file one: from their own letters.

The numbers

From Gain Therapeutics’ yearly reports. Tap a year to see its figures.

Sales and profit

Sales grew from $29,000 in 2020 to $55,000 in 2023, and it lost money every year.
2025
Loss
$20.2 million

Spare cash each year

It spent more cash than it brought in every year: $18.9 million more in 2024.
2025
Not reported
Spare cash is the cash its business brought in, minus what it spent on buildings and equipment. Some years don’t say what it spent, so those bars may be a little high.

What it owns and what it owes

At the end of 2025 it owned $22.8 million, including $20.8 million in cash, and owed $4.25 million.

Key facts

From its yearly report for 2025.
Loss
$20.2 million
Cash in the bank
$20.8 million
Everything it owes
$4.25 million
Year ends
December
Money shown in
U.S. dollars
Latest yearly report
10-K, filed Mar 26, 2026
Figures from Gain Therapeutics’ yearly reports to the SEC (EDGAR), collected Oct 12, 2026.
Not investment advice. Holdings come from public SEC reports and the funds’ own letters, and can be up to 4½ months old. How this works
Privacy policy